Preventive HIV-1 vaccines: where are we going?

Abstract

As more than 15,000 new HIV infections occur daily, mainly in developing countries, social and political will is growing to develop a safe and effective vaccine against the virus and subsequent AIDS disease. The worldwide successes in developing and disseminating vaccines against smallpox and polio raise hopes of the possibility of developing vaccines capable of blocking the transmission of HIV-1. Early attempts to develop HIV-1 vaccines, HIV-1 efficacy trials, immune correlates of protection from HIV-1, live vector-based vaccines, deoxyribonucleic acid (DNA) vaccines, and live attenuated vaccines are discussed. Enthusiasm was renewed at the recent world AIDS conference in Geneva for ongoing..